Prelude Therapeutics (PRLD) Share-based Compensation (2019 - 2026)

Prelude Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at $51000.0 in Q1 2026.

• Quarterly Share-based Compensation rose 920.0% year-over-year to $51000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (down 48.54% YoY) and the FY2025 annual result came in at $11.9 million, down 45.6% from the prior year.
• Share-based Compensation eased to $51000.0 in Q1 2026 per PRLD's latest filing, from $1.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $6.8 million in Q1 2022 and troughed at $5000.0 in Q1 2025.
• A 5-year average of $4.7 million and a median of $5.9 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation slumped 99.91% in 2025, then jumped 920.0% in 2026.
• Over 5 years, Share-based Compensation stood at $5.8 million in 2022, then increased by 1.15% to $5.9 million in 2023, then plunged by 36.16% to $3.8 million in 2024, then tumbled by 51.14% to $1.8 million in 2025, then sank by 97.23% to $51000.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $51000.0, $1.8 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.